Baird raised the firm’s price target on Leidos to $112 from $103 and keeps an Outperform rating on the shares. The firm said they delivered impressive beat and raise 3Q23 results, characterized by healthy margin expansion, better-than-expected FCF generation, and a step-up in long-term expectations within Health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LDOS:
- Leidos price target raised to $136 from $124 at Citi
- Early notable gainers among liquid option names on October 31st
- Leidos raises FY23 EPS view to $6.80-$7.10 from $6.40-$6.80, consensus $6.68
- Leidos Holdings, Inc. Reports Third Quarter Fiscal Year 2023 Results
- Leidos reports Q3 EPS $2.03, consensus $1.67